1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
7 citations
,
December 2010 in “Current Drug Therapy” Anti-complement agents could effectively treat autoimmune diseases with fewer side effects.
Baricitinib is more effective than methotrexate for severe alopecia areata.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
February 2023 in “Acta Scientific Women s Health” New treatments like PBMC, G-CSF, and PRP show promise for helping with repeated implantation failure.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
30 citations
,
April 2007 in “Journal of Leukocyte Biology” Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
April 2023 in “Journal of Investigative Dermatology” Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.
July 2024 in “Journal of Investigative Dermatology”
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
Injecting patients' own PRP into their thyroid improved thyroid function and symptoms in most hypothyroidism cases.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” The treatment was effective for lupus nephritis with manageable side effects.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
January 2026 in “Acta Dermato Venereologica” Dupilumab effectively treats severe skin issues in a rare genetic disorder.